WO2000012623A3 - Use of 5-th receptor antagonists for the treatment of parkinson's disease - Google Patents

Use of 5-th receptor antagonists for the treatment of parkinson's disease Download PDF

Info

Publication number
WO2000012623A3
WO2000012623A3 PCT/EP1999/006219 EP9906219W WO0012623A3 WO 2000012623 A3 WO2000012623 A3 WO 2000012623A3 EP 9906219 W EP9906219 W EP 9906219W WO 0012623 A3 WO0012623 A3 WO 0012623A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
receptor antagonists
parkinson
disease
medicaments
Prior art date
Application number
PCT/EP1999/006219
Other languages
French (fr)
Other versions
WO2000012623A2 (en
Inventor
Carol Routledge
Original Assignee
Smithkline Beecham Plc
Carol Routledge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Carol Routledge filed Critical Smithkline Beecham Plc
Priority to AU59706/99A priority Critical patent/AU5970699A/en
Publication of WO2000012623A2 publication Critical patent/WO2000012623A2/en
Publication of WO2000012623A3 publication Critical patent/WO2000012623A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Use of 5-HT6 receptor antagonists for the preparation of medicaments for the treatment of Parkinson disease.
PCT/EP1999/006219 1998-08-28 1999-08-25 Use of 5-th receptor antagonists for the treatment of parkinson's disease WO2000012623A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59706/99A AU5970699A (en) 1998-08-28 1999-08-25 Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9818914.5 1998-08-28
GBGB9818914.5A GB9818914D0 (en) 1998-08-28 1998-08-28 Use

Publications (2)

Publication Number Publication Date
WO2000012623A2 WO2000012623A2 (en) 2000-03-09
WO2000012623A3 true WO2000012623A3 (en) 2000-08-24

Family

ID=10838073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006219 WO2000012623A2 (en) 1998-08-28 1999-08-25 Use of 5-th receptor antagonists for the treatment of parkinson's disease

Country Status (3)

Country Link
AU (1) AU5970699A (en)
GB (1) GB9818914D0 (en)
WO (1) WO2000012623A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790727B2 (en) 2007-11-02 2010-09-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
PE20020063A1 (en) 2000-06-20 2002-01-30 Upjohn Co BIS-ARYLSULFONES AS LIGANDS OF THE 5-HT RECEPTOR
US6586592B2 (en) 2000-06-20 2003-07-01 Pharmacia & Upjohn Company Bis-arylsulfones
DE60142914D1 (en) * 2000-09-18 2010-10-07 Toa Eiyo Ltd N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
CN100509794C (en) 2001-01-16 2009-07-08 阿斯特拉曾尼卡有限公司 Therapeutic heterocyclic compounds
CA2433950A1 (en) 2001-01-16 2002-07-18 Timothy Davenport Therapeutic chromone compounds
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
IL158593A0 (en) 2001-05-11 2004-05-12 Biovitrum Ab Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
IL159880A0 (en) 2001-08-10 2004-06-20 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht6 receptor affinity
DE60333351D1 (en) * 2002-03-15 2010-08-26 Toa Eiyo Ltd N-SUBSTITUTED BENZOTHIOPHENESULFONAMID DERIVATIVE
TWI465449B (en) 2008-10-23 2014-12-21 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
JP2012525355A (en) 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー Benzenesulfonanilide compounds suitable for treating disorders responsive to modulation of serotonin 5-HT6 receptors
WO2010125136A1 (en) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
JP5718898B2 (en) 2009-04-30 2015-05-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー N-phenyl- (piperazinyl or homopiperazinyl) -benzenesulfonamide or benzenesulfonyl-phenyl- (piperazine or homopiperazine) compounds suitable for treating disorders responsive to modulation of serotonin 5-HT6 receptors
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
KR20160068799A (en) * 2013-10-25 2016-06-15 글락소스미스클라인 엘엘씨 Novel compounds
EP3448430B1 (en) * 2016-04-26 2023-06-07 H. Lundbeck A/S Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533267A1 (en) * 1991-09-18 1993-03-24 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
EP0815861A1 (en) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides and their use
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO1999037623A2 (en) * 1998-01-22 1999-07-29 Smithkline Beecham Plc Sulphonamide derivatives for treatment of cns disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533267A1 (en) * 1991-09-18 1993-03-24 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
EP0815861A1 (en) * 1996-06-28 1998-01-07 F. Hoffmann-La Roche Ag Sulphonamides and their use
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO1999037623A2 (en) * 1998-01-22 1999-07-29 Smithkline Beecham Plc Sulphonamide derivatives for treatment of cns disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOURSON, ANNE ET AL: "Involvement of 5-HT6 receptors in nigro-striatal function in rodents", BR. J. PHARMACOL. (1998), 125(7), 1562-1566, 1998, XP000900090 *
BROMIDGE ET AL: "5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothioph enesulfonamide(SB-271046): A Potent, Selective, and Orally Bioavailable5-HT6 Receptor Antagonist", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 42, no. 2, 28 January 1999 (1999-01-28), pages 202 - 205-205, XP002109186, ISSN: 0022-2623 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; GUPTA Y.K. ET AL: "Therapeutic potentials of 5-HT receptor modulators.", XP002133179, retrieved from STN Database accession no. 94205555 *
INDIAN JOURNAL OF PHARMACOLOGY, (1994) 26/2 (94-107). *
SLEIGHT ET AL: "The 5-hydroxytryptamine-6 receptor: localisation and function", EXPERT OPINION ON THERAPEUTIC PATENTS,GB,ASHLEY PUBLICATIONS, vol. 8, no. 10, 1 October 1998 (1998-10-01), pages 1217 - 1224, XP002093843, ISSN: 1354-3776 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790727B2 (en) 2007-11-02 2010-09-07 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Also Published As

Publication number Publication date
AU5970699A (en) 2000-03-21
WO2000012623A2 (en) 2000-03-09
GB9818914D0 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
WO1999017755A3 (en) Medicaments
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
HUP0004412A3 (en) Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0002902A3 (en) 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions
PL346904A1 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU4345297A (en) Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
ZA983602B (en) Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
HUP0002303A3 (en) Benzofurazan derivatives and their use for the preparation of pharmaceutical compositions which enhance ampa receptor activity
IL119417A0 (en) Drug for Parkinson's disease
AU2639299A (en) Remedies/preventives for parkinson's disease
NO20013645L (en) Use of Pyridazino [4,5-b] Indole-1-Acetamide Derivatives for the Preparation of Medicines for the Treatment of Disease-Related Dysfunction of the Peripheral Benzodiazepine Receptors
EP1126850A4 (en) Treatment of disorders of the outer retina
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
CA2260863A1 (en) Treatment of psychotic disorders
ZA989615B (en) The use of TNF antagonists as drugs for treating septic 39disorders.
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
AU1146401A (en) Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye
ZA98484B (en) Use of beta3-adrenergic receptor agonists for the preparation of healing drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase